Clinical Trials on Severe-Complicated/Fulminant Clostridium Difficile Infection in Japan

Total 6 results

Sanofi Pasteur, a Sanofi Company

Completed

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan

Clostridium Difficile Infection

Japan
Pfizer

Completed

Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults

Clostridium Difficile Associated Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries

Clostridium Difficile Infection

Japan
Astellas Pharma Inc

Completed

A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Clostridium Difficile

Japan
Pfizer

Completed

Clostridium Difficile Vaccine Efficacy Trial (Clover)

Clostridium Difficile Infection

United States, Spain, Belgium, Taiwan, Japan, Portugal, Colombia, Korea, Republic of, Poland, Australia, Germany, Canada, Argentina, Bulgaria, Chile, Czechia, Finland, France, Hungary, Peru, Slovakia, Sweden, United Kingdom
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Clostridium Difficile Infection

Sweden, United States, Mexico, Philippines, Singapore, Germany, France, Canada, Australia, Peru, Colombia, Brazil, Costa Rica, Denmark, Dominican Republic, Finland, Guatemala, Japan, Korea, Republic of, Panama, Poland, Puerto Rico, ... and more

Clinical Trials on Severe-Complicated/Fulminant Clostridium Difficile Infection in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations